Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03080974
PHASE2

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Sponsor: University of Louisville

View on ClinicalTrials.gov

Summary

Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2017-08-14

Completion Date

2029-04-01

Last Updated

2025-10-29

Healthy Volunteers

No

Interventions

DRUG

Nivolumab

Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.

PROCEDURE

Irreversible Electroporation

Non-thermal ablation of tumor

Locations (1)

University of Louisville

Louisville, Kentucky, United States